Further, they showed that either silencing METTL3 by small interfering RNA (siRNA), or inhibiting RNA methylation with neplanocin A, or suppressing ceramide glycosylation is able to re-sensitize the resistant CRC cells to anticancer drugs. This evidence concerns the gene METTL3 and colorectal carcinoma.